Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: Results from a phase 1 study in patients with solid tumors or lymphomas Meeting Abstract
| Authors: | Gounder, M. M.; Bauer, T. M.; Schwartz, G. K.; LoRusso, P.; Kumar, P.; Kato, K.; Tao, B.; Hong, Y.; Patel, P.; Hong, D. |
| Abstract Title: | Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: Results from a phase 1 study in patients with solid tumors or lymphomas |
| Meeting Title: | 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 138 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2020 Oct 24-25 |
| Meeting Location: | Virtual |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-10-01 |
| Start Page: | S3 |
| End Page: | S4 |
| Language: | English |
| ACCESSION: | WOS:000582839900008 |
| PROVIDER: | wos |
| DOI: | 10.1016/s0959-8049(20)31080-7 |
| Notes: | Meeting abstract: 7LBA -- Source: Wos |
